Content about Simon Jose

June 14, 2012

Stiefel, a GlaxoSmithKline company, on Monday acquired the eczema remedy Toctino (alitretinoin) from Basilea Pharmaceutica.

LONDON — Stiefel, a GlaxoSmithKline company, on Monday acquired the eczema remedy Toctino (alitretinoin) from Basilea Pharmaceutica.

“Toctino is an important and growing product that complements the Stiefel portfolio and offers a proven therapy for patients with a significant unmet medical need," stated Simon Jose, Stiefel president. "This acquisition gives us an immediate opportunity to develop and expand the availability of this new and innovative product of value, and reinforces Stiefel and GSK’s commitment to dermatology.”